Ensayos Clínicos **Cabeza y Cuello** abiertos a reclutamiento (Actualizado octubre 2020)

Fuente de información: Clinical trials.gov; EU Clinical Trials Register; REEC (AEMPS)

EudraCT-Number	NCT	CODIGO_ESTUDIO	TITULO_ESTUDIO	FASE	INDICACION	ESTADO	MEDICACION	CENTROS	PROMOTOR	ESPECIALIDAD
2019-002922-60	4282109	**TTCC2019-01/CA209-7HE (NIVOTAX)**	Phase II Multicenter Randomized Trial to Assess the Efficacy and Safety of First Line Nivolumab in Combination With Paclitaxel in Subjects With R/M HNSCC Unable for Cisplatin-based Chemotherapy (NIVOTAX). **1ºLINEA recurrent/metastatic**	Phase II	**Patients unable for cisplatin-based chemotherapy**	**RECLUTANDO**	**NIVOLUMAB**	ICO_Hospitalet (BCN) H.U.Clinic (BCN) ICO_Badalona (BCN) ICO_Girona (BCN) H.Clinico (Madrid) H 12 Octubre (Madrid) H.U.La Fe (Valencia) H.U.Miguel Servet (Zaragoza) C.H.Navarra (Pamplona) H.C.Lozano Blesa(Zaragoza) H.U.V.Rocio (Sevilla) H.R.Universitario (Malaga) H.Clinic Valencia H.U.V.Nieves (Granada) H.U.V.Salud (Toledo) C.H.Salamanca C.O.Galica(Coruña) H.U.Donosti(S.Sebastian) H.U.M.Valdecilla(Santander) H.U.Lucus Augusti(Lugo)	**TTCC**	Oncología_medica
2018-001437-40	3719690	**KO-TIP-007**	El estudio AIM-HN y SEQ-HN: Estudio pivotal no comparativo de 2 cohortes para evaluar la eficacia de tipifarnib en pacientes con **carcinoma de células escamosas de cabeza y cuello (CCECC)** con mutaciones de HRAS (AIM-HN) y el impacto de las mutaciones de HRAS en la respuesta a las terapias sistémicas de primera línea para el CCECC (SEQ-HN).	Phase II	Carcinoma de células escamosas de cabeza y cuello **(CCECC) recurrente o metastásico con mutaciones en HRAS**	**RECLUTANDO**	Tipifarnib (oral)	H.Vall d´Hebron (BCN) H.U.Clinic (BCN) H.U. Sant Pau (BCN) ICO_Hospitalet (BCN) H.del Mar (BCN) H La Paz (Madrid) H 12 Octubre (Madrid) H.U.Sanchinarro(Madrid) H.U.La Fe (Valencia) H.U.Miguel Servet (Zaragoza) C.H.Navarra (Pamplona) H.U.Santiago de Compostela H.U.V.Rocio (Sevilla) H.U.V.Victoria (Malaga) H.Costa del Sol (Malaga)	Kura_Oncology, Inc	Oncología_medica
2019-003060-42	4220866	**1454-002**	A Phase 2 Study in First Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma to Evaluate Intratumoral MK-1454 in Combination With IV Pembrolizumab vs IV Pembrolizumab Monotherapy	Phase II	The purpose of this study is to assess the efficacy and safety of intratumoral (IT) MK-1454 in PLUS pembrolizumab (MK-3475) compared to pembrolizumab alone as a first line treatment of adults with metastatic or unresectable, recurrent head and neck squamous cell carcinoma (HNSCC).	**RECLUTANDO**	MK-3475	H.U.Vall d´Hebron (BCN) H.Clinic (BCN) H.U.Ramon y Cajal(Madrid) H.U.Virgen Victoria (Málaga)	Merck Sharp & Dohme Corp.	Oncología_medica
2018-000789-13	3669718	**ISA101B-HN-01-17**	Estudio de fase II, aleatorizado, con doble enmascaramiento y controlado con placebo de cemiplimab en comparación con la combinación de cemiplimab más ISA101b en el tratamiento de sujetos con **cáncer orofaríngeo (COF) VPH16 -positivo resistente al platino**	Phase II	**Cáncer orofaríngeo** (COF) VPH-16 positivo resistente al platino	**RECLUTANDO**	Human Papilloma Virus (HPV) type 16 E6/E7 synthetic long peptide (SLP®) vaccine	ICO-Hospitalet (BCN) H.U.12-Octubre (Madrid) H.C.Univ.San Carlos (Madrid) H.U.San Chinarro(Madrid) H.U.La Paz (Madrid) H.U.Clinic (BCN) H.U.Vall d´Hebron(BCN) H.U.Salamanca H.U.V.Victoria(Malaga) H.U.M. Valdecilla (Santander)	ISA-Therapeutics B.V	Oncología_medica
2019-002745-38	4529850	**GTI-4419-202**	An Open Label Multi-Center Study of the Effects of Superoxide Dismutase Mimetic GC4419 When Administered to Reduce the Incidence and Severity of Severe Oral Mucositis (SOM) Associated With Chemoradiotherapy for Locally Advanced, Non-Metastatic **Head and Neck Cancer**	Phase II	GTI-4419-202 is a Phase 2 open-label study of the effects of GC4419 when administered IV in combination with IMRT/cisplatin to up to 70 subjects with head and neck cancer, who are at high risk for SOM.	**RECLUTANDO**	GC4419	C.H.Navarra H.U.Vall d´Hebron(BCN) H.U.Ramon y Cajal H.U.12 Octubre(Madrid) H.U.Cruces (Barakaldo) H.U.Fuenlabrada (Madrid) C.U.Salamanca H.U.V.Rocio (Sevilla) H.U.Sanchinarro (Madrid) ICO_Girona	Galera Therapeutics, INC	Oncología Médica/Radioterapica
2019-000569-19	4428151	**MK-7902-009**	A Phase 2, Randomized, Open-label Three-arm Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) That Have Progressed After Platinum Therapy and Immunotherapy (PD-1/PD-L1 Inhibitors) (LEAP-009)	Phase II	Recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) which has progressed after treatment with both platinum therapy and most recently immunotherapy	**RECLUTANDO**	Pembrolizumab & Lenvatinib	ICO-Hospitalet (BCN) H.General Valencia H.U.Vall d´Hebron(BCN) H.U.Ramon y Cajal (Madrid) H.U.Virgen Victoria (Málaga)	Merck Sharp & Dohme Corp.	Oncología_medica
2019-002263-99	4128696	**209229**	A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma	Phase II/III	Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3)	**RECLUTANDO**	GSK3359609 & Pembrolizumab & Placebo	H.U.Clinic(BCN) H.U.Vall d´Hebron (BCN) ICO_Hospitalet (BCN) H.U.V.Victoria(Malaga) H.U.G.Marañon(Madrid) H.U.Ramon y Cajal (Madrid) H.U.La Paz (Madrid) H.U.Quiron (Pozuelo-Madrid) H.U.Miguel Servet (Zaragoza) H.U.Santiago de Compostela H.Clinico Valencia C.U.Navarra	GlaxoSmithKline & Merck Sharp & Dohme Corp.	Oncología_medica
2018-002513-36	3769506	**ASP-1929-301**	A Phase 3, Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional, **Recurrent Head and Neck Squamous Cell Carcinoma in Patients Who Have Failed or Progressed On or After at Least Two Lines of Therapy, of Which at Least One Line Must Be Systemic Therapy**	Phase III	Locoregional, recurrent head and neck squamous cell carcinoma	**RECLUTANDO**	ASP-1929 Photoimmunotherapy	H.U.Sanchinarro (Madrid) H.U.Vall d´Hebron (BCN)	Rakuten Aspyrian, Inc	Oncología_medica
2019-003717-34	4199104	**MK-7902-010**	A Phase 3, Randomized, Placebo-controlled, Double-blind Clinical Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as **1L** Intervention in a PD-L1 Selected Population of Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010).	Phase III	This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma.**ECOG 0-1**	**RECLUTANDO**	Pembrolizumab & Lenvatinib	ICO_Hospitalet (BCN) H.U.Vall d´Hebron (BCN) H.U 12 Octubre (Madrid) H.U.La Paz (Madrid) H.U.L. Blesa (Zaragoza) H.U.V.de Valme (Sevilla)	Merck Sharp & Dohme Corp.	Oncología_medica N=500
2018-001608-12	3645928	**IOV-COM-202**	Estudio Fase II, multicentrico de linfocitos de tumores autologos (LN-144 ó LN-145)en pacientes con **tumores solidos.**	Phase II	Tumores sólidos incluyendo melanoma metastásico avanzado (MM) o irresecable, **carcinoma epidermoide de cabeza y cuello avanzado (CECC)** y cáncer de pulmón no microcítico (CPNM) . **1ºLINEA o SUCESIVAS**	**RECLUTANDO**	Proleukin (i.v) / Pembrolizumab	H.U.Vall d´Hebron (BCN) ICO-Duran i Reynals (BCN) H.U.12 Octubre (Madrid) H.U.SanChinarro (Madrid) H.U.G.Marañon (Madrid) H.U.F. Jimenez Diaz(Madrid) H.R.U.Malaga H.U.M.Valdecilla (Santander)	Iovance Biotherapeutics.Inc	Oncología_medica
2017-005076-26	3485209	**SGNTV-001**	Open label phase 2 study of Tisotumab Vedotin for **locally advanced or metastatic disease in SOLID TUMORS.**	Fase II	4 _COHORTS: Colorectal , NSCLC, Exocrino pancreatic adenocarcinoma and **SCCHN**	**RECLUTANDO**	Tisotumab vedotin (I.V)	H.Vall d´Hebron (BCN) H.U.Ramon y Cajal (Madrid) H.U.Sanchinarro (Madrid) H.Quironsalud (BCN) ICO_Badalona (BCN)	Seattle Genetics, Inc	Oncología_medica
2017-000241-49	3207867	**CNIR178X2201**	A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With **Selected Advanced Solid Tumors** and Non-Hodgkin Lymphoma	Phase II	NSCLC, Non Small Cell Lung Cancer RCC, Renal Cell Cancer Pancreatic Cancer Urothelial Cancer **Head and Neck Cancer** DLBCL, Diffused Large B Cell Lymphoma MSS, Microsatellite Stable Colon Cancer TNBC, Triple Negative Breast Cancer Melanoma	**RECLUTANDO**	NIR178 & PDR001	H.U.Vall d´Hebron(BCN)	Novartis Pharmaceuticals	Oncología_medica
2015-003385-84	2568267	**GO40782 (RXDX-101-02)**	An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements	Phase II	Breast Cancer, Cholangiocarcinoma Colorectal Cancer, **Head and Neck** Neoplasms Lymphoma, Large-Cell, AnaplasticMelanoma ,Neuroendocrine, Tumors Non-Small Cell Lung, CancerOvarian Cancer Pancreatic, **CancerPapillary Thyroid,** CancerPrimary Brain TumorsRenal Cell Carcinoma Sarcomas,**Salivary Gland** Cancers Adult Solid Tumor	**RECLUTANDO**	ENTRECTINIB	H.U.Vall d´Hebron (BCN) H.U.12 Octubre (Madrid) H.U.Ramon y Cajal (Madrid) START Sanchinarro (Madrid) H.U.V.Victoria (Malaga) H.C.U.San Carlos (Madrid) H.U.Virgen Rocio (Sevilla)	Hoffmann-La Roche/ **Ignyta**, Inc	Oncología_medica

EudraCT-Number	NCT	CODIGO_ESTUDIO	TITULO_ESTUDIO	FASE	INDICACION	ESTADO	MEDICACION	CENTROS	PROMOTOR	ESPECIALIDAD
2017-003182-94	3386721	BP40234	An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of RO6874281, an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-A (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors	Phase II	Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers	RECLUTANDO	RO6874281; Atezolizumab; Gemcitabine & Vinorelbine	Clinica U.Navarra|t Hospital del Mar (BCN) H.U. Vall d'Hebron (BCN) START_ Fundacion Jimenez Diaz START_ Sanchinarro	Hoffmann-La Roche	Oncologia_medica
2018-001994-25	3625323	TACTI-002(PO1S);KEYNOTE-PN798	TACTI-002 (Two ACTive Immunotherapeutics): A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurrent PD-X refractory NSCLC or with recurrent or metastatic squamous head and neck cancer (HNSCC) receiving the soluble LAG-3 fusion protein eftilagimod alpha (IMP321) in combination with pembrolizumab (PD-1 antagonist)	Phase II	Recurrent or metastatic squamous head and neck cancer (HNSCC)	RECLUTANDO	IMP321 & Pembrolizumab	H.Santa Creu i Sant Pau (BCN) ICO-Badalona (BCN) H.U.Vall d' Hebron(BCN) F.J.Diaz (Madrid)	IMMUTEP S.A.S	Oncologia_medica
2015-003582-28	2576431	LOXO-TRX-15002(NAVIGATE)	A Phase 2 Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects With NTRK Fusion-positive Tumors	Phase II	The primary objective of this study is to investigate the efficacy of larotrectinib for the treatment of advanced solid tumors harboring a fusion of neurotrophic tyrosine receptor kinase (NTRK) of types 1-3 in **children and adults.** ARM 8 H&N: Larotrectinib will be administered orally as capsule or liquid solution at a dose of 100 mg twice daily in continuing 28-days cycles,	RECLUTANDO	Larotrectinib (LOXO-101)	H.U.Vall d' Hebron(BCN) H.U.Sanchinarro(Madrid) F.Jimenez Diaz (Madrid) H.U. Valdecilla(Santander) H.General de Valencia	Bayer	Onclologia Medica N= 203 **12 years and older**
2015-004535-12	2383927	KO-TIP-001	An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations	Phase II	Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)HRAS Mutant Tumor. Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor	NO RECLUTANDO	Tipifarnib (oral)	H.U.Vall d' Hebron (Barcelona) START H.U.Sanchinarro(Madrid)	Kura_Oncology, Inc	Oncologia_medica
2017-001139-38	3765918	MK3475-689	Estudio de fase III, aleatorizado y abierto para evaluar pembrolizumab como tratamiento neoadyuvante y en combinación con la asistencia habitual como tratamiento adyuvante en el carcinoma epidermoide de cabeza y cuello locorregionalmente avanzado (CECC LA), extirpable, en estadio III-IVA.	Phase III	carcinoma epidermoide de cabeza y cuello locorregionalmente avanzado (CECC LA), extirpable , en estadio III-IVA	RECLUTANDO	Pembrolizumab (iv) / Cisplatin	H.U.de Santiago H.U.La Paz (Madrid) H.U.V.Rocio (Sevilla) ICO-Hospitalet (BCN) ICO-Badalona (BCN) H.U.Vall d' Hebron (BCN)	Merck-Sharp & Dohme Corp.	Oncologia_medica N=704
2017-003302-40	3452137	WO40242	Estudio Fase III,multicentrico, aleatorizado, doble ciego, controlado con placebo de Atezolizumab(anticuerpo Anti-PD-L1)como terapia adyuvante tras terapia local definitiva, en pacientes con carcinoma de cabeza y cuello de celulas escamosas con alto riesgo localmente avanzado.	Phase III	Carcinoma localmente avanzado de células escamosas de la cabeza y el cuello (CCECC)	NO RECLUTANDO	Atezolizumab (iv)	ICO_Badalona (BCN) ICO_Hospitalet (BCN) H.U.Clinic (BCN) H.U.12 Octubre (Madrid) H.C.U.San Carlos (Madrid) H.U.G.Marañon (Madrid) H.U.La Fe (Valencia) H.U.L. Biesa (Zaragoza) H.U.Salamanca H.U.V.de Valme (Sevilla)	Roche Farma S.A.(Soc.Unipersonal)que realiza el ensayo en España y actúa como representante de F. Hoffmann-La Roche LTD	Oncologia_medica
2015-003589-10	2551159	D419LC00001	A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients (KESTREL)	Phase III	Adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) who have not received prior systemic chemotherapy.	NO RECLUTANDO	MEDI4736 Alone or in Combination with Tremelimumab	H.U.Clinic(BCN) H.U.Vall d' Hebron (BCN) ICO_Hospitalet (BCN) H.U.G.Marañon (Madrid) H.U.R y Cajal (Madrid) H.C.U.San Carlos (Madrid) H.U.Lozano Blesa (Zaragoza) H.U.de Jaen	AstraZeneca AB	Oncologia_medica
2017-003702-41	3237325	IDR-0M-02	Estudio pivotal, multinacional, aleatorizado, doble ciego y controlado con placebo, de SGX942 (Dusquetide) para el tratamiento de la mucositis oral en pacientes con carcinoma de células escamosas de cabeza y cuello tratado con quimiorradiación concomitante.	Phase III	Mucositis oral en pacientes con carcinoma de células escamosas de cabeza y cuello tratado con quimiorradiación concomitante. 1ªLINEA	NO RECLUTANDO	Desquetide = SGX942	H.Vall d' Hebron (BCN) H.U.12 Octubre (Madrid) ICO-Girona (BCN) ICO-Badalona(BCN) H.U.Severo Ochoa (Leganes) H.Regional de Malaga H.U.Lozano Blesa (Zaragoza) C.A. Son Espases (P.M) H.Son LLatzer (P.M)	Soligenix UK Limited	Oncologia_medica
2018-003352-20	3768063	BO40729	An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B)	Phase IV	Squamous cell carcinoma of head and neck, Solid Tumors, NSCLC, Urothelial carcinoma, Renal cell carcinoma	RECLUTANDO	Atezolizumab	C.U.Navarra H.U.Sanchinarro (Madrid) H.Sabadell (BCN)	Hoffmann-La Roche	Oncologia_medica
UK	4261179	2019-003825-56	An Exploratory Prospective, Open-label, Unicentric Study With Cross-over Design, Comparing Lymphoseek® vs. Albumin Nanocolloid for Image- Guided Sentinel Lymph Node Mapping in Head and Neck, Melanoma and Breast Cancer.(SENTINELSEEK)	Phase IV	Comparison of the concordance of albumin nanocolloid and Lymphoseek® in the detection of lymph nodes of primary and secondary stage drainage by performing two lymphogammagrams	Not yet recruiting (01/10/20)	Lymphoseek & Nanocoll	H.U.Clinic (BCN)	Fundacion Clinic per a la Recerca Biomédica	Oncologia_medica
UK	4145180	0045-N-16	Effectiveness of a Physical Recovery Program for Head and Neck Cancer Patients (3C-CUIDATE)	Prospectivo	This project intends to carry out an experimental randomized controlled study with 84 patients treated of head and neck cancer who will be assigned randomly to the study groups: a) manual therapy program or, b) control group. The assessment refers to a baseline form (at the beginning of the study), at 6 weeks and at 6 months of patient follow-up.	RECLUTANDO	Manual therapy	Universidad de Granada	Universidad de Granada	
			FASES I & FASES I/II		**FASES I & FASES I/II**			**FASES I & FASES I/II**		
2016-002799-28	3260023	TG4001.12	A phase Ib/II trial evaluating the combination of TG4001 and avelumab in patients with HPV-16 positive recurrent or metastatic malignancies and expansion cohort to oropharyngeal squamous cell carcinoma of the head and neck (SCCHN)	Phase Ib/II	HPV-16 positive recurrent or metastatic malignancies including oropharyngeal squamous cell carcinoma of head and neck, cervical cancer, vulvar cancer, vaginal cancer, penile cancer, anal cancer	NO RECLUTANDO	TG4001 & Avelumab	H.U.12 Octubre (Madrid) H.U.Clinico (Madrid) ICO_Badalona (BCN) H.U.V.Victoria (Malaga) H.U.V.Nieves (Granada) H.U.General d Valencia	TRANSGENE	Oncologia_medica
2017-001792-24	3170960	XL184-021	A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Phase Ib	H&N cancer subjects who have radiographically progressed during or following prior platinum-containing chemotherapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.	RECLUTANDO	atezolizumab & cabozantinib	18 Sites in Spain	Exelixis	Oncologia_medica
2016-001860-12	2900651	CMAK683X2101	A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies	Phase I/II	H&N cancer subjects who have radiographically progressed during or following prior platinum-containing chemotherapy. Prior treatment with ICIs (anti-PD1 or anti-PD-L1) is allowed if given in combination with chemotherapy.	RECLUTANDO	MAK683	H.U.12 Octubre (Madrid)	Novartis Pharmaceuticals	Oncologia_medica
2017-000625-12	3149549	CTMX-M-2009-001	A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)	Phase I/II	The purpose of this first-in-human study of CX-2009 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2009 in adult subjects with metastatic or locally advanced unresectable solid tumors. PROCLAIM: PRObody CLinical Assessment In Man CX-2009 clinical trial 001	NO RECLUTANDO	CX-2009	ICO-Hospitalet(BCN) H.U.Clinic (BCN) C.U.Navarra (Pamplona) H.U.San Chinarro (Madrid) IVO (Valencia)	CytomX Therapeutics	Oncologia_medica
2018-000390-67	3637764	ACT15377	Estudio en fase 1/2, abierto, multicéntrico, para evaluar la seguridad, eficacia preliminar y farmacocinética de isatuximab (SAR650984) en combinación con atezolizumab o solo isatuximab en pacientes con enfermedades malignas avanzadas	Phase I/II	Otros	NO RECLUTANDO	Isantumab (i.v)	ICO_Hospitalet (BCN) H.U.Clinic (BCN) H.U.Vall d' Hebron (BCN) C.U.de Navarra H.U.12 Octubre(Madrid) M.D.Anderson (Madrid) Unidad Start_CIOCC(Madrid) Unidad Start_FiDiaz (Madrid)	Sanofi_ aventis reserche &Developpment	Oncologia_medica

EudraCT-Number	NCT	CODIGO_ESTUDIO	TITULO_ESTUDIO	FASE	INDICACION	ESTADO	MEDICACION	CENTROS	PROMOTOR	ESPECIALIDAD
2016-004989-25	3126110	**INCAGN1876-201**	Estudio de fase I/II sobre la seguridad, la tolerabilidad y la eficacia de INCAGN01876 en combinación con inmunoterapias en sujetos con **neoplasias malignas avanzadas o metastásicas**	Phase I/II	**F I**: cáncer cuello uterino, endometrio, gástrico ,carcinoma hepatocelular, melanoma (mucosal o cutaneo), carcinoma células Merkel, mesotelioma, cáncer colorrectal, carcinoma pulmón no microcítico , cáncer ovario, **carcinoma epidermoide cabeza/cuello** , cáncer microcítico pulmón , carcinoma cél renales , cáncer mama triple negativo y carcinoma urotelial avanzados o metastásicos. **F II**: cáncer endometrio, gástrico y **CECC avanzados o metastásicos,** (tumores alternativos autorizades Monitor médico). **2ªLINEA**	**NO RECLUTANDO**	INCAGN01876	ICO_Badalona (BCN) H.U.Clinic (BCN) H.U.Vall d´Hebron (BCN) H.U.12 Octubre (Madrid) H.U.Ramon y Cajal (Madrid) H.U.Sanchinarro (Madrid) H.U.V.Victoria (Malaga) H.U.Reina Sofia (Cordoba) H.U.M. Valdecilla(Santander) C.U.Navarra(Pamplona)	Incyte Biosciences International Sarl.	Oncologia_medica
2017-001475-23	3289962	**GO39733**	A phase 1a/1b, open-label, dose escalation study of the safety and PKs of RO7198457 as a single agent and in combination with Atezolizumab in patients with **locally advanced or metastatic Tumors.**	Phase Ia/Ib	8_COHORTS: Melanoma, Bladder Ca, NSCLC, Colorectal, Triple Negative Breast Ca, Renal Ca, **H&N Cancer** , other Solid Cancers.	**RECLUTANDO**	Atezolizumab (iv) RO7198457	H.U.Vall d´Hebron (BCN) Clinica.U.Navarra (Pamplona)	Genentech,Inc	Oncologia_medica
2018-003402-63	**3917381**	**GCT1046-01**	First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors	Ph1, first-in-human (FIH) and an expansion part (phase 2a)	The trial is an open-label, multi-center safety trial of GEN1046. The trial consists of two parts, a dose escalation part (phase 1, first-in-human (FIH) and an expansion part (phase 2a)). The expansion part of the trial will be initiated once the Recommended Phase 2 Dose (RP2D) has been determined	**RECLUTANDO**	**GEN1046 (i.v)**	Clinica.U.de Navarra H.U.Vall d´Hebron (BCN) START-FJD(Madrid) START-CIOCC(Madrid) H.Clinico de Valencia H.U.12 Octubre (Madrid)	Genmab A/S	Oncologia_medica
2018-001095-38	3799744	**ICO-VCN-H&N_2018**	A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of VCN-01 in Combination With Durvalumab (MEDI4736) in Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the **Head and Neck**	Phase I	Metastasis & Recurrence	**RECLUTANDO**	Genitic:VCN-01 Biological: Durvalumab	ICO_Hospitalet H.U.Vall d´Hebron	**ICO** ***Collaborators:*** VCN Biosciencces S.L BioClever 2005 S.L Astra Zeneca	Oncologia_medica N= 20
2016-002219-16	2988960	**M15-862**	A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumor	Phase I	Advanced, solid tumors, squamous cell cancer of the **head and neck**, pancreatic cancer, non-small cell lung cancer, melanoma	**RECLUTANDO**	ABBV-927 & ABBV-181	H.U.Sanchinarro (Madrid) H.U.Puerta de Hierro (Madrid) H.U.La Fe (Valencia) F. Jimenez Diaz (Madrid)	AbbVie	Oncologia_medica
2019-000446-36	3894618	**SL01-DEL-101**	Phase 1 Dose Escalation and Dose Expansion Study of an Agonist Redirected Checkpoint Fusion Protein, SL-279252 (PD1-Fc-OX40L), in Subjects With **Advanced Solid Tumors** or Lymphomas	Phase I	**Squamous Cell Carcinoma of the Head and Neck**. MelanomaNon Small Cell Lung CancerUrothelial CarcinomaGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaSquamous Cell Carcinoma of the AnusSquamous Cell Carcinoma of the CervixSquamous Cell Carcinoma of the SkinRenal Cell CarcinomaHodgkin LymphomaDiffuse Large B Cell LymphomaMismatch Repair Deficient or MSI-High Solid Tumors	**RECLUTANDO**	SL-279252	H.U.Vall d´Hebron (Barcelona)	Shattuck Labs, Inc.	Oncologia_medica
2011-000495-33	1351103	**CLGK974X2101**	A Phase I, Open-label, Dose Escalation Study of Oral LGK974 in Patients With Malignancies Dependent on Wnt Ligands	Phase I	This primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given to adult patients with selected solid malignancies for whom no effective standard treatment is available.	**RECLUTANDO**	Drug:LGK974 Biological: PDR001	2 Sites Barcelona 2 Sites Madrid	Novartis Pharmaceuticals	Oncologia_medica
2018-004334-15	**4234113**	**SC103**	A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in **Patients With Selected Advanced/Metastatic Solid Tumors**	Phase I	**HNSCC & Thyroid**, A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors	**RECLUTANDO**	SO-C101 Pembrolizumab	H.U.Vall d´Hebron(BCN)	SOTIO	Oncologia_medica
2019-003167-22	**4196283**	M19-894	A Phase 1b, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Subjects With **Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma**	Phase I	The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with **recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).**	**RECLUTANDO**	ABBV-368 Tilsotolimod Nab-paclitaxel ABBV-181	H.U.Clinic (BCN) H.U.Fuenlabrada (Madrid) H.U.12 Octubre (Madrid) Start_San Chinarro (Madrid) H.U.Virgen Victoria (Málaga)	AbbVie	Oncologia_medica
2018-001146-34	3260322	**8374-CL-0101**	A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors	Phase I	Advanced and serious forms of cancers such as **head and neck cancers**, non-small cell lung cancers, prostate cancer, ovarian cancer, colorectal cancer and gastric cancer	**NO RECLUTANDO**	ASP8374 & Pembrolizumab	H.U.Clinic(BCN) H.U.Vall d´Hebron (BCN) ICO_Hospitalet (BCN) Start Sanchinarro(Madrid) Start_F.J.Diaz (Madrid) H.del Mar(BCN) H.U.V.Victoria(Malaga) H.U.V.Rocio(Sevilla) H.U.G.Marañon(Madrid)	Astellas Pharma Global Development INC Astellas.	Oncologia_medica
2017-002242-77	**3509012**	**D933BC00001(CLOVER)**	A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With **Advanced Solid Tumors** (CLOVER)	Phase I	**Carcinoma epidermoide de cabeza y cuello** (CECC); CPNM y CPM.	**NO RECLUTANDO**	Durvalumab + Cisplatino	H.U.G.Marañon (Madrid) H.U.V.Victoria (Malaga) ICO_Badalona (BCN)	AstraZeneca AB	Oncologia_medica
2019-000478-45	3893955	**M19-037**	A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors	Phase I	Advanced Solid, TumorsTriple-Negative Breast Cancer (TNBC),Non-small-cell-lung-cancer (NSCLC),**Head and Neck Squamous Cell Carcinoma** (HNSCC), Metastatic Solid Tumors	**Not yet recruiting (01/10/20)**	ABBV-927; ABBV-368; ABBV-181; Docetaxel	H.Vall d´Hebron (BCN) F. Jimenez Diaz (Madrid) C.I.O.C.Campal (Madrid)	AbbVie	Oncologia_medica